T. Rowe Price Associates
ANIP icon

T. Rowe Price Associates’s ANI Pharmaceuticals ANIP Stock Holding History

T. Rowe Price Associates’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.04M Buy
13,483
+2,930
+28% +$229K ﹤0.01% 2135
2025
Q4 		$834K Buy
10,553
+850
+9% +$73.6K ﹤0.01% 2156
2025
Q3 		$889K Buy
9,703
+481
+5% +$39.2K ﹤0.01% 2122
2025
Q2 		$602K Buy
9,222
+1,133
+14% +$73.8K ﹤0.01% 2217
2025
Q1 		$542K Buy
8,089
+801
+11% +$47.8K ﹤0.01% 2220
2024
Q4 		$403K Buy
7,288
+1,220
+20% +$70K ﹤0.01% 2373
2024
Q3 		$363K Buy
6,068
+186
+3% +$11.3K ﹤0.01% 2389
2024
Q2 		$375K Buy
5,882
+1,713
+41% +$111K ﹤0.01% 2308
2024
Q1 		$289K Buy
+4,169
New +$252K ﹤0.01% 2449

Other funds holding ANIP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

T. Rowe Price Associates's ANIP Position: Q1 2026 in Review

T. Rowe Price Associates increased its ANI Pharmaceuticals (ANIP) stake by 28% in Q1 2026, buying an estimated $229K and bringing the position to 13,483 shares worth $1.04M. The position accounts for ﹤0.01% of the portfolio, ranked #2135.

T. Rowe Price Associates first reported a position in ANIP in Q1 2024 and has held it in 9 quarters since. 280 funds tracked by Wall St. Rank hold ANIP as of Q1 2026.

  • T. Rowe Price Associates held 13,483 shares of ANI Pharmaceuticals worth $1.04M as of Q1 2026.
  • T. Rowe Price Associates bought 2,930 ANI Pharmaceuticals shares in Q1 2026, an estimated $229K.
  • ANI Pharmaceuticals made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2135 holding.
  • T. Rowe Price Associates first reported a position in ANI Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
  • 280 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.